Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Dementia - Pipeline Review, H1 2019 - ResearchAndMarkets.com

March 22, 2019

DUBLIN--(BUSINESS WIRE)--Mar 22, 2019--The “Dementia - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Dementia - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 17, 20, 48, 17 and 3 respectively.

Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System)
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Topics Covered

  1. Introduction
  2. Dementia - Overview
  3. Dementia - Therapeutics Development
  4. Dementia - Therapeutics Assessment
  5. Dementia - Companies Involved in Therapeutics Development
  6. Dementia - Drug Profiles
  7. Dementia - Dormant Projects
  8. Dementia - Discontinued Products
  9. Dementia - Product Development Milestones

Companies Mentioned

  • Acadia Pharmaceuticals Inc
  • Acorda Therapeutics Inc
  • Actinogen Medical Ltd
  • Adamed Sp z oo
  • AgeneBio Inc
  • Alector Inc
  • Allergan Plc
  • Anavex Life Sciences Corp
  • Asceneuron SA
  • Axon Neuroscience SE
  • Axovant Sciences Ltd
  • Biogen Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Bolder Biotechnology Inc
  • Cortice Biosciences Inc
  • CSPC NBP Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Denali Therapeutics Inc
  • DiaMedica Therapeutics Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ensol Biosciences Inc
  • EVER Neuro Pharma GmbH
  • GW Pharmaceuticals Plc
  • H. Lundbeck AS
  • HSRx Group
  • Hyundai Pharmaceutical Co Ltd
  • Immungenetics AG
  • Ionis Pharmaceuticals Inc
  • IRLAB Therapeutics AB
  • Ironwood Pharmaceuticals Inc
  • Johnson & Johnson
  • M3 Biotechnology Inc
  • MediPost Co Ltd
  • MGC Pharmaceuticals Ltd
  • Neuraltus Pharmaceuticals Inc
  • Neurimmune Holding AG
  • NeuroScientific Biopharmaceuticals Ltd
  • Oryzon Genomics SA
  • Otsuka Holdings Co Ltd
  • P2D Inc
  • Pacific Northwest Biotechnology LLC
  • Pharmasum Therapeutics AS
  • Prana Biotechnology Ltd
  • ProMIS Neurosciences Inc
  • Prothena Corp Plc
  • Resverlogix Corp
  • Rodin Therapeutics Inc
  • and more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/q68lkb/dementia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190322005250/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/22/2019 09:57 AM/DISC: 03/22/2019 09:57 AM